Emergent BioSolutions
Update in progressEBS (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Emergent BioSolutions is a life sciences company that develops preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States and abroad. It offers commercial and medical countermeasure products, including ACAM2000, BioThrax, CYFENDUS, Raxibacumab, ANTHRASIL, BAT, Ebanga, TEMBEXA, CNJ-016, and NARCAN/KLOXXADO nasal sprays, plus contract development and manufacturing services. Founded 1998, based in Gaithersburg, MD.
Company score
- Sentiment
- -0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.04
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.41
- Governance
- -0.69
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.28
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!